abstract |
The present invention relates to crystalline forms of the compound 3-{4-[2-(4-tert-butoxycarbonylaminophenyl)ethoxy]phenyl}-(S)-2-ethoxy propanoic acid as shown in formula (I), or a pharmaceutically acceptable salt thereof, and any solvates thereof. The invention also concerns methods of treating one or more metabolic diseases, particularly those associated with Insulin Resistance Syndrome, and the use of the crystalline form of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof, in the manufacture of a medicament for therapeutic use in one or more metabolic diseases. The invention further concerns pharmaceutical compositions containing the crystalline form of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as active ingredient, as well as processes for the manufacture of the crystalline form of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof. |